Israel - English - Ministry of Health

teva israel ltd - lenalidomide as hydrochloride hydrate - hard capsule - lenalidomide as hydrochloride hydrate 10 mg - lenalidomide - multiple myeloma (mm): lenalidomide teva is indicated for the treatment of multiple myeloma.myelodysplastic syndromes: lenalidomide teva is indicated for patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes (mds) associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities.lenalidomide teva 7.5 mg is not indicated for treatment in mds.mantle cell lymphoma:lenalidomide teva is indicated for the treatment of adult patients with relapsed and/or refractory mantle cell lymphoma (mcl).follicular lymphoma:lenalidomide teva in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma.

Israel - English - Ministry of Health

teva israel ltd - lenalidomide as hydrochloride hydrate - hard capsule - lenalidomide as hydrochloride hydrate 15 mg - lenalidomide - multiple myeloma (mm): lenalidomide teva is indicated for the treatment of multiple myeloma.myelodysplastic syndromes: lenalidomide teva is indicated for patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes (mds) associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities.lenalidomide teva 7.5 mg is not indicated for treatment in mds.mantle cell lymphoma:lenalidomide teva is indicated for the treatment of adult patients with relapsed and/or refractory mantle cell lymphoma (mcl).follicular lymphoma:lenalidomide teva in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma.

Israel - English - Ministry of Health

teva israel ltd - lenalidomide as hydrochloride hydrate - hard capsule - lenalidomide as hydrochloride hydrate 2.5 mg - lenalidomide - multiple myeloma (mm): lenalidomide teva is indicated for the treatment of multiple myeloma.myelodysplastic syndromes: lenalidomide teva is indicated for patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes (mds) associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities.lenalidomide teva 7.5 mg is not indicated for treatment in mds.mantle cell lymphoma:lenalidomide teva is indicated for the treatment of adult patients with relapsed and/or refractory mantle cell lymphoma (mcl).follicular lymphoma:lenalidomide teva in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma.

Israel - English - Ministry of Health

teva israel ltd - lenalidomide as hydrochloride hydrate - hard capsule - lenalidomide as hydrochloride hydrate 20 mg - lenalidomide - multiple myeloma (mm): lenalidomide teva is indicated for the treatment of multiple myeloma.myelodysplastic syndromes: lenalidomide teva is indicated for patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes (mds) associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities.lenalidomide teva 7.5 mg is not indicated for treatment in mds.mantle cell lymphoma:lenalidomide teva is indicated for the treatment of adult patients with relapsed and/or refractory mantle cell lymphoma (mcl).follicular lymphoma:lenalidomide teva in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma.

Israel - English - Ministry of Health

teva israel ltd - lenalidomide as hydrochloride hydrate - hard capsule - lenalidomide as hydrochloride hydrate 25 mg - lenalidomide - multiple myeloma (mm): lenalidomide teva is indicated for the treatment of multiple myeloma.myelodysplastic syndromes: lenalidomide teva is indicated for patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes (mds) associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities.lenalidomide teva 7.5 mg is not indicated for treatment in mds.mantle cell lymphoma:lenalidomide teva is indicated for the treatment of adult patients with relapsed and/or refractory mantle cell lymphoma (mcl).follicular lymphoma:lenalidomide teva in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma.

Israel - English - Ministry of Health

teva israel ltd - lenalidomide as hydrochloride hydrate - hard capsule - lenalidomide as hydrochloride hydrate 5 mg - lenalidomide - multiple myeloma (mm): lenalidomide teva is indicated for the treatment of multiple myeloma.myelodysplastic syndromes: lenalidomide teva is indicated for patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes (mds) associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities.lenalidomide teva 7.5 mg is not indicated for treatment in mds.mantle cell lymphoma:lenalidomide teva is indicated for the treatment of adult patients with relapsed and/or refractory mantle cell lymphoma (mcl).follicular lymphoma:lenalidomide teva in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma.

Israel - English - Ministry of Health

teva israel ltd - lenalidomide as hydrochloride hydrate - hard capsule - lenalidomide as hydrochloride hydrate 7.5 mg - lenalidomide - multiple myeloma (mm): lenalidomide teva is indicated for the treatment of multiple myeloma.myelodysplastic syndromes: lenalidomide teva is indicated for patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes (mds) associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities.lenalidomide teva 7.5 mg is not indicated for treatment in mds.mantle cell lymphoma:lenalidomide teva is indicated for the treatment of adult patients with relapsed and/or refractory mantle cell lymphoma (mcl).follicular lymphoma:lenalidomide teva in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma.

Australia - English - Department of Health (Therapeutic Goods Administration)

teva pharma australia pty ltd - lenalidomide hydrochloride monohydrate, quantity: 18.15 mg - capsule - excipient ingredients: microcrystalline cellulose; indigo blue; titanium dioxide; croscarmellose sodium; gelatin; purified talc; colloidal anhydrous silica; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; purified water; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - multiple myeloma (mm),lenalidomide-teva is indicated for the treatment of multiple myeloma.,myelodysplastic syndromes (mds),lenalidomide-teva is indicated for treatment of patients with transfusion-dependent anaemia due to low- or intermediate-1 risk myelodysplastic syndromes associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities.

Australia - English - Department of Health (Therapeutic Goods Administration)

teva pharma australia pty ltd - lenalidomide hydrochloride monohydrate, quantity: 12.1 mg - capsule - excipient ingredients: colloidal anhydrous silica; gelatin; croscarmellose sodium; iron oxide yellow; purified talc; microcrystalline cellulose; titanium dioxide; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; purified water; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - multiple myeloma (mm),lenalidomide-teva is indicated for the treatment of multiple myeloma.,myelodysplastic syndromes (mds),lenalidomide-teva is indicated for treatment of patients with transfusion-dependent anaemia due to low- or intermediate-1 risk myelodysplastic syndromes associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities.

Australia - English - Department of Health (Therapeutic Goods Administration)

teva pharma australia pty ltd - lenalidomide hydrochloride monohydrate, quantity: 6.05 mg - capsule - excipient ingredients: colloidal anhydrous silica; gelatin; purified talc; microcrystalline cellulose; croscarmellose sodium; titanium dioxide; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; purified water; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - multiple myeloma (mm),lenalidomide-teva is indicated for the treatment of multiple myeloma.,myelodysplastic syndromes (mds),lenalidomide-teva is indicated for treatment of patients with transfusion-dependent anaemia due to low- or intermediate-1 risk myelodysplastic syndromes associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities.